

SYNNESTVEDT & LECHNER LLP

In re application of V. Ramakrishna, et al.

Application No. 10/006,177

S&L File P30,631 USA

September 13, 2005

Page 2

Amendments to the Claims

1. (Currently amended) An isolated oligopeptide or peptide comprising at least one epitopic peptide comprising the amino acid sequence of SEQ ID NO: 4, said oligopeptide or peptide comprising from 8 to about 30 amino acid residues, wherein said oligopeptide or peptide binds to class I MHC molecules or can be processed to bind to class I MHC molecules.

2. (Previously presented) The oligopeptide of claim 1 wherein said oligopeptide comprises at least two epitopic peptides.

3. (Previously presented) The oligopeptide of claim 1 wherein said oligopeptide comprises at least three epitopic peptides.

4. (Canceled).

5. (Previously presented) An isolated oligopeptide or peptide comprising at least one epitopic peptide, said epitopic peptide comprising one amino acid difference from SEQ ID NO: 4.

6. (Original) The oligopeptide or peptide of claim 5 wherein said one amino acid difference is the result of a conservative amino acid substitution.

SYNNESTVEDT & LECHNER LLP

In re application of V. Ramakrishna, et al.
Application No. 10/006,177

S&L File P30,631 USA
September 13, 2005
Page 3

7. (Previously presented) The oligopeptide or peptide of claim 5 wherein said one amino acid difference is the substitution of one hydrophobic amino acid with another hydrophobic amino acid.

8. (Previously presented) The oligopeptide or peptide of claim 5 wherein said amino acid difference is the addition or deletion of one amino acid to or from said epitopic peptide.

9. (Withdrawn) An immunogen comprising a member selected from the group consisting of Mage D protein and an immunologically active fragment of Mage D protein.

10. (Withdrawn) A polynucleotide comprising a polynucleotide selected from the group consisting of:

- (a) a polynucleotide that encodes a polypeptide selected from the group consisting of the polypeptides of claims 1, 2, 3, 4, 5, 6, 7, 8, and 9, and
- (b) the full complement of (a).

11. (Withdrawn) The polynucleotide of claim 10 wherein the polynucleotide of (a) is a DNA.

12. (Withdrawn) The polynucleotide of claim 10 wherein the polynucleotide of (a) is an RNA.

SYNNESTVEDT & LECHNER LLP

In re application of V. Ramakrishna, et al.
Application No. 10/006,177

S&L File P30,631 USA
September 13, 2005
Page 4

13. (Withdrawn) A vector comprising a polynucleotide of claim 10.
14. (Withdrawn) A mammalian cell comprising the vector of claim 13 and expressing said polynucleotide.
15. (Currently amended) A vaccine composition comprising an oligopeptide or peptide of claim 1, 2, 3, 5, 6, 7, or 8 present in a pharmaceutically acceptable carrier and in an amount sufficient to elicit production of antibodies or cells that react with said oligopeptide or peptide when said oligopeptide or peptide is administered to an immunologically competent animal.
16. (Withdrawn) An antibody specific for an immunogen of claim 1, 2, 3, 4, 5, 6, 7, 8, or 9.
17. (Withdrawn) A process for inducing a cytotoxic T lymphocyte (CTL) in vitro that is specific for a tumor cell expressing HLA-A1 comprising contacting a precursor CTL with an immunogen of claim 1 under conditions that generate a CTL response to the tumor cell.
18. (Withdrawn) A process for inducing a CTL response in vitro that is specific for a tumor cell expressing HLA-A1, said process comprising contacting a precursor CTL with a mammalian cell of claim 14.

SYNNESTVEDT & LECHNER LLP

In re application of V. Ramakrishna, et al.
Application No. 10/006,177

S&L File P30,631 USA
September 13, 2005
Page 5

19. (Withdrawn) A process for treating a subject with cancer characterized by tumor cells expressing HLA-A1, said process comprising administering CTLs induced by the processes of claims 17 or 18 in an amount sufficient to destroy the tumor cells through direct lysis or to effect the destruction of the tumor cells indirectly through the elaboration of cytokines.

20. (Withdrawn) A process for treating a cancer-afflicted subject characterized by tumor cells expressing any class I MHC molecule and a gene coding for an epitopic sequence of at least one of SEQ ID NO: 17-20, whereby the CTLs of claim 17 are administered in an amount sufficient to destroy the tumor cells through direct lysis or to effect the destruction of the tumor cells indirectly through the elaboration of cytokines.

21. (Withdrawn) A process for inducing a cytotoxic T lymphocyte (CTL) in vitro that is specific for a tumor cell expressing HLA-A2 comprising contacting a precursor CTL with an immunogen of claim 1 under conditions that generate a CTL response to the tumor cell.

22. (Withdrawn) A process for inducing a CTL response in vitro that is specific for a tumor cell expressing HLA-A2, said process comprising contacting a precursor CTL with a mammalian cell of claim 14.

SYNNESTVEDT & LECHNER LLP

In re application of V. Ramakrishna, et al.
Application No. 10/006,177

S&L File P30,631 USA
September 13, 2005
Page 6

23. (Withdrawn) A process for treating a subject with cancer characterized by tumor cells expressing HLA-A2, said process comprising administering CTLs induced by the processes of claims 21 or 22 in an amount sufficient to destroy the tumor cells through direct lysis or to effect the destruction of the tumor cells indirectly through the elaboration of cytokines.

24. (Withdrawn) A process for treating a cancer-afflicted subject characterized by tumor cells expressing any class I MHC molecule and a gene coding for an epitopic sequence of at least one of SEQ ID NO: 1-16, whereby the CTLs of claim 21 are administered in an amount sufficient to destroy the tumor cells through direct lysis or to effect the destruction of the tumor cells indirectly through the elaboration of cytokines.

25. (Withdrawn) The process for claims 19, 20, 23 or 24 wherein said cancer is carcinoma.

26. (Withdrawn) The process for claims 19, 20, 23 or 24 wherein said cancer is ovarian carcinoma.

27. (Withdrawn) A process for inducing a CTL response in a subject, said process comprising administering at least one immunogen of claim 1, 2, 3, 4, 5, 6, 7, 8 or 9, including combinations thereof, to an HLA-A1 positive subject and in an amount sufficient to induce a CTL response to tumor cells expressing HLA-A1.

SYNNESTVEDT & LECHNER LLP

In re application of V. Ramakrishna, et al.
Application No. 10/006,177S&L File P30,631 USA
September 13, 2005
Page 7

28. (Withdrawn) A process for inducing a CTL response in a subject, said process comprising administering at least one immunogen of claim 1, 2, 3, 4, 5, 6, 7, 8 or 9, including combinations thereof, to an HLA-A2 positive subject and in an amount sufficient to induce a CTL response to tumor cells expressing HLA-A2.

29. (Currently amended) An immunogen consisting essentially of the amino acid sequence of SEQ ID NO: 4.

30. (Previously presented) The oligopeptide of claim 2, said oligopeptide comprising a first epitopic peptide and a second epitopic peptide, wherein said first epitopic peptide comprises the amino acid sequence of SEQ ID NO: 4 and said second epitopic peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-20.